Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Anthropic IPO Marketing Expected to Start in Mid-October 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Milei Threatens Falkland Oil Firms With Sanctions 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Add as a preferred source on Google
CRANBURY, N.J., Feb. 21, 2018 -- Amicus Therapeutics (Nasdaq:FOLD) today announced a conference call and live audio webcast on Wednesday, February 28, 2018 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2017.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international), conference ID: 9598004.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on February 28, 2018. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 9598004.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. The cornerstone of the Amicus portfolio is migalastat, an oral precision medicine for people living with Fabry disease who have amenable genetic mutations. Migalastat is currently approved under the trade name Galafold™ in the European Union, with additional approvals granted and pending in several geographies. The lead biologics program of the Amicus pipeline is ATB200/AT2221, a novel, late-stage, potential best-in-class treatment paradigm for Pompe disease. The Company is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
CONTACTS:
Investors/Media:
Amicus Therapeutics
Sara Pellegrino, IRC
Senior Director, Investor Relations
[email protected]
(609) 662-5044
Media:
Pure Communications
Jennifer Paganelli
[email protected]
(347) 658-8290
FOLD–G
